antibodies .- online.com





anti-Actin-Like 7A antibody



| | Θ_{W} |
|--|--------------|
| | |
| | |

| Overview | |
|-------------------|---|
| Quantity: | 100 μL |
| Target: | Actin-Like 7A (ACTL7A) |
| Reactivity: | Human |
| Host: | Rabbit |
| Clonality: | Polyclonal |
| Conjugate: | This Actin-Like 7A antibody is un-conjugated |
| Application: | Western Blotting (WB) |
| Product Details | |
| Immunogen: | Recombinant protein encompassing a sequence within the center region of human ACTL7A. The exact sequence is proprietary. |
| Isotype: | IgG |
| Cross-Reactivity: | Mouse |
| Purification: | Purified by antigen-affinity chromatography. |
| Target Details | |
| Target: | Actin-Like 7A (ACTL7A) |
| Alternative Name: | actin like 7A (ACTL7A Products) |
| Background: | Actin like 7A, The protein encoded by this gene is a member of a family of actin-related proteins |
| | (ARPs) which share significant amino acid sequence identity to conventional actins. Both actins and ARPs have an actin fold, which is an ATP-binding cleft, as a common feature. The ARPs are |

| | involved in diverse cellular processes, including vesicular transport, spindle orientation, nuclear |
|-------------------|---|
| | migration and chromatin remodeling. This gene (ACTL7A), and related gene, ACTL7B, are |
| | intronless, and are located approximately 4 kb apart in a head-to-head orientation within the |
| | familial dysautonomia candidate region on 9q31. Based on mutational analysis of the ACTL7A |
| | gene in patients with this disorder, it was concluded that it is unlikely to be involved in the |
| | pathogenesis of dysautonomia. The ACTL7A gene is expressed in a wide variety of adult |
| | tissues, however, its exact function is not known. [provided by RefSeq] |
| Molecular Weight: | 49 kDa |
| Gene ID: | 10881 |
| UniProt: | Q9Y615 |

Application Details

| Application Notes: | WB: 1:500-1:3000. Optimal dilutions/concentrations should be determined by the researcher. |
|--------------------|--|
| | Not tested in other applications. |
| Comment: | Positive Control: NIH-3T3 |
| Restrictions: | For Research Use only |

Handling

| Format: | Liquid |
|--------------------|--|
| Concentration: | 1 mg/mL |
| Buffer: | 1XPBS (pH 7), 1 % BSA, 20 % Glycerol, 0.01 % Thimerosal |
| Preservative: | Thimerosal (Merthiolate) |
| Precaution of Use: | This product contains Thimerosal (Merthiolate): a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
| Storage: | 4 °C,-20 °C |
| Storage Comment: | Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles. |